|
"許駿"的相關文件
顯示項目 61-85 / 145 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2012 |
Changes of Pulmonary Fluorodeoxyglucose Uptake After Neoadjuvant Concurrent Chemoradiation in Predicting Postoperative Pulmonary Complications for Patients With Esophageal Cancer
|
Hsu, F.; Cheng, J.; Lee, J.; Huang, P.; Hsu, C.; Lin, C.; Tsai, Y.; Tzen, K.; Yen, R.; 曾凱元; 成佳憲; 顏若芳; 蔡育傑; 許駿; 李章銘; 黃培銘; 許峰銘 |
| 國立臺灣大學 |
2012 |
CHLORHEXIDINE FOR THE PREVENTION OF BLOODSTREAM INFECTION (BSI) ASSOCIATED WITH PERMANENTLY IMPLANTABLE VENOUS PORTS (PORT-A) IN SOLID CANCER PATIENTS: A PROSPECTIVE COHORT STUDY
|
Kao, H.; Chen, I.; Chang, S.; Hong, M.; Chien, S.; Hu, F.; Hsu, C.; Yeh, K.; 許駿 |
| 國立臺灣大學 |
2012 |
CYCLIN E1 SUPPRESSION CONTRIBUTES TO SORAFENIB-INDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA (HCC)
|
Hsu, C.; Ou, D.; Cheng, Y.; Lin, Y.; Chang, Y.; Yeh, K.; Cheng, A.; 鄭安理; 許駿; 歐大諒 |
| 國立臺灣大學 |
2011 |
Activation of Checkpoint Kinase 2 (Chk2) Contributes to the Antitumour Synergy between Igf1 Receptor Kinase Inhibitor Nvp-Aew541 and Sunitinib in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010-07 |
多向度問卷之設計、翻譯與測試
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華 |
| 國立臺灣大學 |
2010 |
Bortezomib Suppresses Focal Adhesion Kinase Expression Via Interrupting Nuclear Factor-Kappa B
|
柯博升; 張孜菁; 陳建宏; 劉佳佳; 郭呈欽; 許駿; 沈盈君; 沈湯龍; 徐松錕; 劉俊揚; KO, BO-SHENG; CHANG, TZU-CHING; CHEN, CHIEN- HUNG; LIU, CHIA-CHIA; KUO, CHENG-CHIN; HSU, CHIUN; SHEN, YING-CHUN; SHEN, TANG-LONG; SHYUE, SONG-KUN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2010 |
Adjuvant Interferon Therapy after Curative Therapy for Hepatocellular Carcinoma (Hcc): A Meta-Regression Approach
|
沈盈君; 許駿; 陳立宗; 鄭佳綺; 胡賦强; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHEN, LI-TZONG; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma
|
邵幼雲; 林宗哲; 許駿; 沈盈君; 徐志宏; 鄭安理; SHAO, YU-YUN; LIN, ZONG-ZHE; HSU, CHIUN; SHEN, YING-CHUN; HSU, CHIH-HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Efficacy and Tolerability of Bevacizumab Plus Capecitabine as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
|
徐志宏; 許駿; 陳培哲; 林宗哲; 趙祖怡; 鄭安理; HSU, CHIH-HUNG; HSU, CHIUN; CHEN, PEI-JER; LIN, ZONG-ZHE; CHAO, TSU-YI; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (Dce-Mri) to Predict Treatment Outcomes for Advanced Hepatocellular Carcinoma (Hcc) Patients Who Received Sorafenib Plus Tegafur/Uracil Therapy
|
沈盈君; 許昭禹; 游治維; 許駿; 徐志宏; 鄭安理; 施庭芳; SHEN, YING-CHUN; HSU, CHAO-YU; YU, CHIH-WEI; HSU, CHIUN; HSU, CHIH-HUNG; CHENG, ANN-LII; SHIH, TIFFANY TING-FANG |
| 國立臺灣大學 |
2010 |
Geographic Difference in Survival Outcome for Advanced Hepatocellular Carcinoma: Implications on Future Clinical Trial Design
|
許駿; 沈盈君; 鄭佳綺; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; CHENG, CHIA-CHI; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Molecular Targeted Therapy for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives
|
沈盈君; 許駿; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Phase Ii Study of Combining Sorafenib with Metronomic Tegafur/Uracil for Advanced Hepatocellular Carcinoma
|
徐志宏; 沈盈君; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 許駿; 鄭安理; HSU, CHIH-HUNG; SHEN, YING-CHUN; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Predictive and Prognostic Values of Tau and Ercc1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
|
邵幼雲; 郭冠廷; 胡賦强; 盧彥伸; 黃俊升; 廖肇裕; 許駿; 郭文宏; 張金堅; 林璟宏; 鄭安理; SHAO, YU-YUN; KUO, KUAN-TING; HU, FU-CHANG; LU, YEN-SHEN; HUANG, CHIUN-SHENG; LIAU, JAO-YU; HSU, CHIUN; KUO, WEN-HONG; CHANG, KING-JEN; LIN, CHING -HUNG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Preventive Effect of Anti-Viral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Meta -Regression Approach
|
鄭佳綺; 沈盈君; 許駿; 胡賦强; 鄭安理; CHENG, CHIA-CHI; SHEN, YING-CHUN; HSU, CHIUN; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2010 |
Treatment Outcomes for Synchronous or Metachronous Hypopharyngeal/ Laryngeal/Oropharyngeal Cancer and Esophageal Cancer
|
許駿; 王駿瑋; 成佳憲; HSU, CHIUN; WANG, CHUN-WEI; CHENG, JASON CHIA-HSIEN |
| 國立臺灣大學 |
2010 |
Induction of DNA Damage-Inducible Gene Gadd45 Beta Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
|
歐大諒; 沈盈君; 俞松良; 陳昆鋒; 葉培彥; 林亮音; 許駿; 鄭安理; OU DA-LIANG; SHEN YING-CHUN; YU SUNG-LIANG; CHEN KUEN-FENG; YEH PEI-YEN; LIN LIANG-IN; HSU CHIUN; CHENG ANN-LII |
| 國立臺灣大學 |
2010 |
Design, Translation, and Test of Multi-Dimensional Questionnaires
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華; CHIE, WEI-CHU; HSU, CHIUN; Y.C.CHANG; CHEN, G SHAO-YI; KAO, TZE-WAH |
| 國立臺灣大學 |
2010 |
Potentiating the Anti-Tumor Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Signaling Pathway
|
歐大諒; 許駿; 沈盈君; 鄭安理; OU, DA-LIANG; HSU, CHIUN; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
The Aurora Kinase Inhibitor Ve-465 Has Anticancer Effects in Pre-Clinical Studies of Human Hepatocellular Carcinoma
|
許輝吉; 徐志宏; 葉培彥; 黃繼瑩; 郭頌鑫; 許駿; 胡賦強; 鄭永銘; 鄭安理; HSU, HEY-CHI; HSU, CHIH-HUNG; YEH, PEI-YEN; HUANG, CHI-YING; KUO, SUNG-HSIN; HSU, CHIUN; HU, FU-CHANG; JENG, YUNG-MING; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival
|
沈盈君; 胡賦強; 鄭永銘; 張毓廷; 林宗哲; 章明珠; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
INDUCTION OF BIM EXPRESSION CONTRIBUTES TO THE ANTITUMOR SYNERGY BETWEEN SORAFENIB AND MITOGEN-ACTIVATED PROTEIN KINASE/EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE INHIBITOR CI-1040 IN HEPATOCELLULAR CARCINOMA
|
歐大諒; 沈盈君; 梁嘉德; 劉俊陽; 俞松良; 盧彥伸; 許駿 |
| 國立臺灣大學 |
2009 |
Induction of Bim Expression Contributes to the Antitumor Synergy between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal- Regulated Kinase Kinase Inhibitor Ci-1040 in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 梁嘉德; 劉俊揚; 俞松良; 盧彥伸; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; LIANG, JA-DER; LIOU, JUN-YANG; YU, SUNG-LIANG; LU, YEN-SHEN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Overexpressed Focal Adhesion Kinase Predicts a Higher Incidence of Extrahepatic Metastasis and Worse Survival in Hepatocellular Carcinoma
|
詹以吉; 柯博升; 許駿; 王約翰; 劉俊揚; JAN, YEE-JEE; KO, BO-SHENG; HSU, CHIUN; WANG, JOHN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bevacizumab (B) and Erlotinib (E) in Combination for Asian Patients (Pts) with Advanced/Metastatic Hepatocellular Carcinoma ( Hcc): An Interim Safety Report
|
徐志宏; 邱宗傑; 許駿; 鄭安理; HSU, CHIH-HUNG; CHIOU, TZEON-JYE; HSU, CHIUN; CHENG, ANN-LII |
顯示項目 61-85 / 145 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
|
